Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12623679 | 0.97 | RARB (0.39) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL1812836 | 0.97 | RARB (0.44) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL31515421 | 0.97 | RARB (0.41) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12625463 | 0.97 | RARB (0.41) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL3439570 | 0.97 | RARB (0.41) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12624695 | 0.96 | RARB (0.46) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12624693 | 0.96 | RARB (0.46) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12624692 | 0.96 | RARB (0.46) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12624694 | 0.96 | RARB (0.46) | RARBRARARARGS1PR1S1PR3 | |
| SCHEMBL12624698 | 0.96 | RARB (0.46) | RARBRARARARGS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CFAP20, KIF20A, KIF20B | RARB 2364/4885RARA 1623/4885RARG 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.